Phase 1 trial of GD2-SADA: 177 Lu-DOTA drug complex in patients with recurrent or refractory metastatic solid tumors known to express GD2 including small cell lung cancer (SCLC), sarcoma, and malignant melanoma.

Details

Language :

English

ISSN :

0732183X

Volume :

41

Database :

Supplemental Index

Journal :

Journal of Clinical Oncology

Publication Type :

Academic Journal

Accession number :

164018190

Full Text :

https://doi.org/10.1200/JCO.2023.41.16_suppl.TPS3162